Brokerages predict that ConforMIS Inc (NASDAQ:CFMS) will post sales of $19.36 million for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for ConforMIS’s earnings. The highest sales estimate is $19.43 million and the lowest is $19.29 million. ConforMIS reported sales of $19.10 million in the same quarter last year, which would suggest a positive year over year growth rate of 1.4%. The business is expected to report its next quarterly earnings report on Wednesday, August 7th.

On average, analysts expect that ConforMIS will report full year sales of $82.28 million for the current year, with estimates ranging from $82.05 million to $82.51 million. For the next fiscal year, analysts anticipate that the business will report sales of $89.87 million, with estimates ranging from $89.36 million to $90.37 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover ConforMIS.

ConforMIS (NASDAQ:CFMS) last issued its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.12). ConforMIS had a negative net margin of 42.90% and a negative return on equity of 97.85%. The firm had revenue of $20.64 million during the quarter, compared to the consensus estimate of $20.11 million.

A number of brokerages have recently issued reports on CFMS. Zacks Investment Research downgraded shares of ConforMIS from a “buy” rating to a “hold” rating in a research report on Monday, May 6th. Oppenheimer set a $4.00 price objective on shares of ConforMIS and gave the company a “buy” rating in a research report on Thursday, May 2nd. Finally, BTIG Research reissued a “buy” rating and set a $3.00 price objective on shares of ConforMIS in a research report on Thursday, May 2nd. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $3.00.

In related news, CEO Mark A. Augusti sold 25,477 shares of ConforMIS stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $2.72, for a total transaction of $69,297.44. Following the transaction, the chief executive officer now owns 1,123,698 shares in the company, valued at approximately $3,056,458.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Paul S. Weiner sold 12,612 shares of ConforMIS stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $2.72, for a total transaction of $34,304.64. Following the transaction, the chief financial officer now owns 568,629 shares in the company, valued at approximately $1,546,670.88. The disclosure for this sale can be found here. In the last three months, insiders have sold 80,801 shares of company stock valued at $222,106. Insiders own 3.38% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CFMS. Renaissance Technologies LLC lifted its stake in shares of ConforMIS by 10.0% during the 3rd quarter. Renaissance Technologies LLC now owns 3,306,461 shares of the medical instruments supplier’s stock valued at $3,505,000 after buying an additional 299,561 shares in the last quarter. Vanguard Group Inc lifted its stake in shares of ConforMIS by 1.3% during the 3rd quarter. Vanguard Group Inc now owns 2,230,254 shares of the medical instruments supplier’s stock valued at $2,364,000 after buying an additional 28,556 shares in the last quarter. Gabelli Funds LLC lifted its stake in shares of ConforMIS by 76.2% during the 4th quarter. Gabelli Funds LLC now owns 104,056 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 45,000 shares in the last quarter. Acadian Asset Management LLC lifted its stake in shares of ConforMIS by 26.0% during the 4th quarter. Acadian Asset Management LLC now owns 127,166 shares of the medical instruments supplier’s stock valued at $45,000 after buying an additional 26,202 shares in the last quarter. Finally, Tibra Equities Europe Ltd purchased a new position in shares of ConforMIS during the 1st quarter valued at $381,000. Institutional investors own 30.35% of the company’s stock.

Shares of CFMS stock traded down $0.07 during mid-day trading on Wednesday, reaching $3.37. 539,443 shares of the company’s stock traded hands, compared to its average volume of 1,339,134. ConforMIS has a 12 month low of $0.36 and a 12 month high of $3.84. The company has a debt-to-equity ratio of 0.64, a current ratio of 3.00 and a quick ratio of 2.33. The company has a market cap of $233.45 million, a price-to-earnings ratio of -4.55 and a beta of 3.05.

ConforMIS Company Profile

Conformis, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee.

Featured Story: What are gap-down stocks?

Get a free copy of the Zacks research report on ConforMIS (CFMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.